The 1-year high price for the company’s stock is recorded $16.42 on 01/03/22, with the lowest value was $2.09 for the same time period, recorded on 05/23/22. Stock analysis for Tabula Rasa HealthCare Inc (TRHC:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. had a pretty Dodgy run when it comes to the market performance. $125 million of the purchase price was paid at the closing of the acquisition, excluding certain adjustments related to the net working capital of the PrescribeWellness business, and up to an additional $15 million will be paid if certain performance-based metrics are met during the fiscal years ending December 31, 2023, and 2024. (“TDS”) for an all-cash purchase price of up to $140 million. Tabula Rasa HealthCare, Inc.® (“TRHC” or the “Company”) (NASDAQ: TRHC), a leading healthcare technology company advancing the safe use of medications, announced today that it completed the previously announced sale of its PrescribeWellness business to Transaction Data Systems, Inc.
![tabula rasa stock tabula rasa stock](https://craftpeak-commerce-images.imgix.net/2021/02/SM-21-02-Abstract-Tabula-copy.jpg)
The Stock rose vividly during the last session to $4.44 after opening rate of $3.68 while the lowest price it went was recorded $3.61 before closing at $3.76.Recently in News on August 1, 2022, Tabula Rasa HealthCare Completes Sale of PrescribeWellness to Transaction Data Systems for $140 Million. Medication risk management is TRHC’s leading offering, and its cloud. (TRHC), which is $4.33 to be very precise. Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. The latest closing stock price for Tabula Rasa.
![tabula rasa stock tabula rasa stock](https://www.normanrecords.com/artwork/large/167/140917-einsturzende-neubauten-tabula-rasa.jpg)
Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions.Let’s start up with the current stock price of Tabula Rasa HealthCare Inc. Historical daily share price chart and data for Tabula Rasa Healthcare since 2022 adjusted for splits. The views and opinions expressed in this article are those of the authors, and do not represent the views of. Chart price data is provided by TradingView on a 15-minute delayed basis. Analysts estimate an earnings decrease this quarter of 0.11 per share, a decrease next quarter of 0.00 per. Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Tabula Rasa HealthCare Forecast Revenue Growth. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info. Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week. For the first quarter of 2019, Tabula Rasa generated total revenue of 61 million, a 39 increase year over year. Analysts expect adjusted earnings to reach -0.910 per share for the current fiscal year. Year-over-year quarterly sales growth most recently was 14.1. Tabula Rasa HealthCare Inc’s trailing 12-month revenue is 321.7 million with a -27.3 profit margin. For more news on the financial markets be sure to visit Equities News. Currently, Tabula Rasa HealthCare Inc’s price-earnings ratio is. To get more information on Tabula Rasa HealthCare Inc and to follow the company's latest updates, you can visit the company's profile page here: Tabula Rasa HealthCare Inc's Profile. Its solutions are trusted by health plans and pharmacies to help drive value-based payment results. TRHC's extensive clinical tele-pharmacy network improves care for patients nationwide.
![tabula rasa stock tabula rasa stock](http://s1.bwallpapers.com/wallpapers/2014/07/29/tabula-rasa-pc-game_090204241.jpg)
The company reported quarterly sales of 72.60 million which beat the analyst consensus estimate of 68. TRHC's technology solutions, including DoseMeRx™ and MedWise™, improve patient outcomes, reduce hospitalizations, and lower healthcare costs. Tabula Rasa HealthCare (NASDAQ:TRHC) reported quarterly losses of (0.53) per share which missed the analyst consensus estimate of (0.12) by 341.67 percent.This is a 5200 percent decrease over losses of (0.01) per share from the same period last year. Tabula Rasa HealthCare provides medication safety solutions that empower healthcare professionals to optimize medication regimens and reduce medication-related risk, specifically targeting adverse drug events.